Nothing Special   »   [go: up one dir, main page]

Müller et al., 2020 - Google Patents

Past, present and future of oncolytic reovirus

Müller et al., 2020

View HTML
Document ID
7212106064977588895
Author
Müller L
Berkeley R
Barr T
Ilett E
Errington-Mais F
Publication year
Publication venue
Cancers

External Links

Snippet

Simple Summary Within this review article the authors provide an unbiased review of the oncolytic virus, reovirus, clinically formulated as pelareorep. In particular, the authors summarise what is known about the molecular and cellular requirements for reovirus …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Similar Documents

Publication Publication Date Title
Müller et al. Past, present and future of oncolytic reovirus
Burman et al. Newcastle disease virus at the forefront of cancer immunotherapy
Marchini et al. Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade
Choi et al. From benchtop to bedside: a review of oncolytic virotherapy
Rahman et al. Oncolytic virotherapy with myxoma virus
Kuryk et al. From conventional therapies to immunotherapy: melanoma treatment in review
Chaurasiya et al. Oncolytic virotherapy for cancer: clinical experience
Schirrmacher Fifty years of clinical application of Newcastle disease virus: time to celebrate!
Aldrak et al. Oncolytic herpes simplex virus-based therapies for cancer
Turnbull et al. Evidence for oncolytic virotherapy: where have we got to and where are we going?
Fournier et al. Oncolytic Newcastle disease virus as cutting edge between tumor and host
Malogolovkin et al. Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes
Kemp et al. Exploring reovirus plasticity for improving its use as oncolytic virus
Atasheva et al. Cytokine responses to adenovirus and adenovirus vectors
Calton et al. Oncolytic viruses for multiple myeloma therapy
Singh et al. Emerging prevention and treatment strategies to control COVID-19
Wang et al. Radiotherapy as a new player in immuno-oncology
Evgin et al. Parking CAR T cells in tumours: oncolytic viruses as valets or vandals?
Sostoa et al. Oncolytic viruses as a platform for the treatment of malignant brain tumors
Bourhill et al. Going (reo) viral: Factors promoting successful reoviral oncolytic infection
Angelova et al. Parvovirus-based combinatorial immunotherapy: a reinforced therapeutic strategy against poor-prognosis solid cancers
Malfitano et al. Virotherapy as a potential therapeutic approach for the treatment of aggressive thyroid cancer
Hofman et al. The multifaceted role of macrophages in oncolytic virotherapy
Muthukutty et al. Oncolytic virus engineering and utilizations: cancer immunotherapy perspective
Simon et al. Serotype-specific killing of large cell carcinoma cells by reovirus